Monitoring the population at risk when detecting MGUS with abnormal kappa/lambda ratio using cardiac (NT-proBNP) and renal (urinary albumin) biomarkers has been shown to be effective in AL amyloidosis [41,42], but scanty evidence supports the value of risk and prognostic stratification for non-AL amyloidosis. The gene discussed is NPPB; the disease is AL amyloidosis.